Evidence map›Paper›PMID 39000181›Full record

ArticleInternational journal of molecular sciences2024

Exosome Therapy: A Novel Approach for Enhancing Estrogen Levels in Perimenopause.

Samar Alkhrait, Mervat M Omran, Mohammad Mousaei Ghasroldasht, Hang-Soo Park, Riham Katkhuda, Ayman Al-Hendy

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Samar AlkhraitDepartment of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.ORCID 0009-0001-1349-7621
Mervat M OmranDepartment of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
Mohammad Mousaei GhasroldashtDepartment of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
Hang-Soo ParkDepartment of Biomedical Science, Sunchon National University, Suncheon-si 57922, Republic of Korea.
Riham KatkhudaDepartment of Pathology, University of Chicago, Chicago, IL 60637, USA.
Ayman Al-HendyDepartment of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0002-8778-4447

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Perimenopause significantly impacts women's health globally, often managed with hormone replacement therapy (HRT) despite the associated risks. This study explores a novel alternative exosome therapy, aimed at stimulating estrogen production in ovarian tissues, thus offering a potential non-hormonal treatment for perimenopausal symptoms. Employing ex vivo methodologies, ovarian cortex specimens from perimenopausal women were treated with exosomes derived from human umbilical cord mesenchymal stem cells and cultured under specific conditions (patent number: PCT/US2022/073467). The exosomes were produced under cyclic guanosine monophosphate (cGMP) conditions, ensuring high safety standards. Estrogen levels were quantified using enzyme-linked immunosorbent assay (ELISA), and gene expression changes in estrogen and follicle-stimulating hormone (FSH) receptors were assessed via quantitative polymerase chain reaction (PCR). Immunohistochemistry (IHC) was utilized to evaluate cellular proliferation and apoptotic markers. The results indicated a significant increase in estrogen levels and estrogen receptor-alpha (Erα) expression in treated tissues compared to controls. Additionally, a decrease in apoptotic markers and an increase in cellular proliferation markers were observed. These findings suggest that exosome therapy can effectively enhance estrogen production and modulate receptor sensitivity in perimenopausal ovarian tissues. This approach could serve as a safer alternative to HRT, aligning with the body's natural regulatory mechanisms and potentially offering a more effective treatment option for managing perimenopausal symptoms.

Indexed as

EstrogensExosomesPerimenopauseApoptosisCell ProliferationEstrogen Receptor alphaFemaleHumansMesenchymal Stem CellsMiddle AgedOvaryReceptors, FSHEstrogen Receptor alphaEstrogensReceptors, FSHestrogenexosomeperimenopause

Identifiers

PMID39000181
PMCPMC11240923

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.